Stockscreener 앱 받기
2.2703
2.50%
0.0703
전일 마감가:
$2.20
열려 있는:
$2.14
하루 거래량:
9,924
Relative Volume:
0.01
시가총액:
$5.33M
수익:
-
순이익/손실:
$-11.28M
주가수익비율:
-0.7543
EPS:
-3.01
순현금흐름:
$-9.78M
1주 성능:
+4.40%
1개월 성능:
+5.87%
6개월 성능:
-71.60%
1년 성능:
-62.32%
1일 변동 폭
$2.08
$2.25
1주일 범위
$2.07
$2.25
52주 변동 폭
$1.62
$14.67
Ensysce Biosciences Inc Stock (ENSC) Company Profile
명칭
Ensysce Biosciences Inc
전화
(858) 263-4196
주소
7946 IVANHOE AVENUE, LA JOLLA
ENSC을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ENSC
Ensysce Biosciences Inc
|
2.25 | 5.00M | 0 | -11.28M | -9.78M | -3.01 |
|
VRTX
Vertex Pharmaceuticals Inc
|
476.77 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
574.48 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
326.70 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
573.83 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.32 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Ensysce Biosciences Inc 주식(ENSC)의 최신 뉴스
What analysts say about Ensysce Biosciences Inc. stockConsistently profitable trades - jammulinksnews.com
When (ENSC) Moves Investors should Listen - news.stocktradersdaily.com
Ensysce Biosciences Inc. Stock Analysis and ForecastUnprecedented profits - jammulinksnews.com
Is Ensysce Biosciences Inc. a good long term investmentConsistent wealth multiplication - jammulinksnews.com
What drives Ensysce Biosciences Inc. stock priceRobust financial gains - jammulinksnews.com
Ensysce Biosciences initiates Phase 3 study of PF614 - TipRanks
FDA-Reviewed Phase 3 Trial Begins: Revolutionary Opioid Promises Pain Relief Without Abuse Risk - Stock Titan
What makes Ensysce Biosciences Inc. stock price move sharplySolid Return Trade Selections - Newser
Why Ensysce Biosciences Inc. stock attracts strong analyst attentionFree Professional Portfolio Management - Newser
How Ensysce Biosciences Inc. stock performs during market volatilityHigh Yield Stock Selection - Newser
NAVY(boat pilot token) Tokenomics ExplainedHigh Return Potential - Newser
Where are the Opportunities in (ENSC) - news.stocktradersdaily.com
Travere Therapeutics (NASDAQ:TVTX) and Ensysce Biosciences (NASDAQ:ENSC) Head to Head Comparison - Defense World
FDA-Designated Breakthrough Pain Drug Advances: New Solution to Opioid Overdose Crisis Shows Promise - Stock Titan
(ENSC) Investment Analysis - news.stocktradersdaily.com
Short Interest in Ensysce Biosciences, Inc. (NASDAQ:ENSC) Declines By 71.5% - Defense World
Leading Pain Experts Reveal New Opioid Abuse Prevention Technology at World's Largest Pain Conference - Stock Titan
(ENSC) On The My Stocks Page - news.stocktradersdaily.com
Ensysce Biosciences (NASDAQ:ENSC) Trading 1.7% Higher – Here’s What Happened - Defense World
ensysce biosciences appoints baker tilly as new auditor By Investing.com - Investing.com South Africa
ensysce biosciences appoints baker tilly as new auditor - Investing.com
Ensysce Flat on Receiving Grant - Baystreet.ca
Ensysce Biosciences secures additional $5.3M NIDA grant - Investing.com Australia
Ensysce Biosciences secures additional $5.3M NIDA grant By Investing.com - Investing.com Canada
Ensysce Biosciences (ENSC) Secures $5.3M Grant to Advance Opioid Development | ENSC Stock News - GuruFocus
Revolutionary Opioid With Built-in Overdose Protection Secures $5.3M NIH Grant After FDA Breakthrough Status - Stock Titan
Ensysce Biosciences (NASDAQ:ENSC) Raised to Hold at Wall Street Zen - Defense World
Zacks Small Cap Analysts Boost Earnings Estimates for ENSC - Defense World
Ensysce Biosciences Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Ensysce Biosciences Advances in Pain Relief Innovation - TipRanks
Ensysce Biosciences: Is Now the Time to Bet on a Turnaround? - AInvest
Revolutionary Opioid Treatment Proves Overdose-Proof in Clinical Trials, Secures Key Patent - Stock Titan
Ensysce Biosciences Bolsters Management Team with Regulatory Expert - Stock Titan
Ensysce Biosciences Inc (ENSC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.79%
0.24%
자본화:
|
볼륨(24시간):